Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

New England Journal of Medicine

Volumn 370, Issue 24, 2014, Pages 2295-2306

  Mease, Philip J ^a   Genovese, Mark C ^c   Greenwald, Maria W ^d   Ritchlin, Christopher T ^f   Beaulieu, André D ^g   Deodhar, Atul ^b   Newmark, Richard ^e   Feng, Jing Yuan ^e   Erondu, Ngozi ^e   Nirula, Ajay ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Desert Medical Advances   (United States)

^e AMGEN INC   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; PLACEBO;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AORTA STENOSIS; ARTHRALGIA; ARTICLE; BACTERIAL ARTHRITIS; BREAST CARCINOMA; BRONCHITIS; CELLULITIS; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-17;

EID: 84902209516     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1315231     Document Type: Article

References (39)

1. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10. (Pubitemid 28265412)
2. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151-8. (Pubitemid 32954441)
3. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53:511-8. (Pubitemid 9004521)
4. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013;25:287-96.
5. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-13. (Pubitemid 34596683)
6. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64:Suppl 2:ii14-ii17. (Pubitemid 40288513)
7. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
8. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7. (Pubitemid 41113349)
9. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36. [Erratum, Arthritis Rheum 2005;52:2951.] (Pubitemid 40530131)
10. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
11. Waisman A. To be 17 again - anti-interleukin-17 treatment for psoriasis. N Engl J Med 2012;366:1251-2. [Erratum, N Engl J Med 2012;367:93.]
12. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
13. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
14. Bluett J, Barton A. What have genome-wide studies told us about psoriatic arthritis? Curr Rheumatol Rep 2012;14:364-8.
15. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359:419-29.
16. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. Phenotypic and functional features of Th-17 cells in psoriasis and psoriatic arthritis. In: Program and abstracts of the American College of Rheumatology Annual Scientific Meeting, San Francisco, October 24-29, 2008. abstract.
17. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58:2307-17.
18. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012;18:1069-76.
19. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21.
20. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73:349-56.
21. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
22. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72:Suppl 2:ii116-ii123.
23. Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012;132:2466-9.
24. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
25. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
26. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
27. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-R806.
28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
29. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91. (Pubitemid 351679544)
30. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
31. Ware J Jr, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. User's manual for the SF-36v2TM Health Survey. 2nd ed. Lincoln, RI: QualityMetric, 2007.
32. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
33. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat 2013;24:356-60.
34. Martin ML, McCarrier KP, Chiou CF, et al. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat 2013;24:255-60.
35. Introductory guide: MEDRA version 15.1. September 2012 (http://www.meddra.org/sites/default/files/guidance/file/intguide-15-1-English- 0.pdf).
36. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. June 2010 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8. 5x11.pdf).
37. Pavelka K, Chon Y, Newmark R, Erondu N, Lin S-LA. Randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. In: Program and abstracts of the American College of Rheumatology Annual Scientific Meeting, Washington, DC, October 24-29, 2012. abstract.
38. Targan SR, Feagan BG, Vermeire S, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. Gastroenterology 2012;143(3):e26.
39. von Vietinghoff S, Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol 2008;181:5183-8.